Invivyd (IVVD): 10 Best NASDAQ Stocks Under $5 to Buy Right Now

Invivyd Inc. (NASDAQ:IVVD) is one of the best NASDAQ stocks under $5 to buy right now. On May 14, Invivyd reported earnings for Q1 2026, highlighted by $13.7 million in PEMGARDA net product revenue, which marks a 22% growth compared to Q1 2025. The company ended the quarter with $184.2 million in cash and cash equivalents, supplemented by ~$20 million in gross proceeds from an April at-the-market offering. R&D expenses rose to $30.7 million, and selling, general, & administrative expenses increased to $25.1 million, resulting in a net loss of $41.4 million for the quarter.

The increase in operating expenses was primarily driven by the ongoing DECLARATION Phase 3 clinical trial for VYD2311, an investigational COVID-19 monoclonal antibody candidate. Initial full enrollment for the trial was achieved in March, and a subsequent sample size re-estimation in April added ~500 subjects, shifting the anticipation of top-line data to Q3. Based on an ad hoc safety review, the trial’s Independent Data Monitoring Committee recommended reducing post-dose monitoring from two hours to thirty minutes, eliminated certain follow-up visits, and updated eligibility to include pregnant and breastfeeding women.Invivyd (IVVD): 10 Best NASDAQ Stocks Under $5 to Buy Right Now

In laboratory assessments, both PEMGARDA and VYD2311 showed continued in vitro neutralizing activity against the SARS-CoV-2 BA.3.2.2 (“Cicada”) variant. Looking forward, Invivyd Inc. (NASDAQ:IVVD) is preparing for the LIBERTY Phase 3 trial comparing VYD2311 to mRNA vaccines, a Phase 2 trial for Long COVID and vaccine injury, and pediatric evaluations via the DRUMMER trial. Beyond COVID-19, the company is advancing its pipeline with development plans for VMS063 for measles and VBY329 for pediatric respiratory syncytial virus/RSV prophylaxis, targeting investigational new drug readiness for both candidates in late 2026.

Invivyd Inc. (NASDAQ:IVVD) develops next‑generation antibody drugs aimed at long‑lasting effectiveness against evolving viruses, utilizing a proprietary platform to deliver durable therapies.

While we acknowledge the potential of IVVD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

View Comments